• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Authors » Colin Stoecker

Colin Stoecker

Articles

ARTICLES

Protocol button

NIH Online Tool Strengthens Protocol Collaboration

January 3, 2020
Colin Stoecker

An updated protocol writing tool developed by NIH and TransCelerate aims to help the clinical trials industry write better protocols. While it won’t necessarily help the clarity of writing, it does lay out a template to help guide the work.

Currently, 2,400 active users are developing protocols with the help of NIH’s e-Protocol Writer, an online tool that walks teams of investigators through protocol development, making sure they apply scientific standards required by NIH and the FDA as well as standards of good clinical practice, such as ICH E6 and E8.

Read More
Effect of Proctocol chart

Major Problems Leading to Phase 3 Failures 

January 1, 2020
Colin Stoecker

Some daunting statistics from the last decade: 38 percent of phase 3 trials failed; 59 percent of trials did not advance from phase 1 to phase 2 and 35 percent of trials entering phase 2 did not move to phase 3.

“Most drugs are in clinical phases for five to seven years,” said Ken Getz, director of sponsored research programs at the Tufts Center for the Study of Drug Development. “This is extremely costly — but not easy to calculate since it includes the cost of all phase 1, 2 and 3 activity. ... The typical drug costs several hundred million dollars in direct costs to carry through all clinical testing phases.”

Read More
FDA_Logo-360x240.png

Standard of Evidence Expanded in New FDA Guidance

December 22, 2019
Colin Stoecker
The FDA yesterday proposed broadening its definition of the standard of evidence for effectiveness of investigational drugs and increasing the range of acceptable trial design, especially in rare disease research. Read More
Impact of Age on Clinical Research Understanding Image

Increasing Diversity in Trials Requires Understanding Special Populations

December 15, 2019
Colin Stoecker
A new survey on diversity in clinical trials found that older people are more likely to be asked by their doctors to participate in a clinical trial than their younger counterparts. More than half of older patients were asked by their doctor to participate in a clinical trial compared to 30 percent of patients 34 years or younger. Read More
Phone App

Device Apps Present Unique Risks in Trials

December 8, 2019
Colin Stoecker
As the use of commercial apps in clinical trials mushrooms, sites will need to work more closely with their IRBs to be sure using those apps doesn’t slow down a trial. Read More
China on Global

U.S. Tops List of Trial Startups With China Making Progress in Phase 1

December 8, 2019
Colin Stoecker
China is rapidly making headway in phase 1 clinical trials, although the U.S. remains the world leader in phase 1 through 3 trials overall. Read More
Top 10

Novartis Retains Top Spot in CNS Summit Innovation Index

December 2, 2019
Colin Stoecker

For the second year in a row Novartis has been named the most innovative pharma company in the industry by the Innovation Index, a collaboration between CNS Summit and IDEA Pharma.

“The differentiator between Novartis and the competition was the nature of these innovative initiatives, which showed strong potential to be transformative, rather than incremental,” said a report on the index, which measures companies’ advances in trial optimization, clinical innovation and use of digital technology.

Read More
ICH Logo

ICH Overhauls 22-Year-Old Clinical Studies Guideline

November 24, 2019
Leslie Ramsey and Colin Stoecker
For the first time in 22 years, the International Council on Harmonization (ICH) is almost completely overhauling the guideline ICH E8 — General Considerations for Clinical Studies, the international standard for designing and developing trials. Read More
Performance chart

CRO Overall Performance Slightly Improved, But Still Low in Key Areas, Survey Says

November 22, 2019
Colin Stoecker

The following summary of CenterWatch’s 2019 Global Site Relationship Survey presents sites’ views on the CROs they work with. In last month’s issue, we provided details on their sponsor relationship views, as well as data on the types, locations and therapeutic areas of the site responding to the survey (CenterWatch Monthly, November 2019).

Sites are looking for improvements in almost all areas of their working relationships with CROs, but particularly in the areas of contracting and budget, according to a new CenterWatch survey.

Read More
Rocket study startup

Mayo’s Startup Acceleration Project Cuts Timelines Dramatically

November 15, 2019
Colin Stoecker
Mayo Clinic has cut its study start up times by two-thirds, thanks to administrative restructuring, staff education and new technology. Read More
View All Articles by Colin Stoecker

Upcoming Events

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing